As of May 2023, the EMA (European Medicines Agency) had approved several CAR T-cell therapies. Some of the approved treatments included:
- Kymriah (tisagenlecleucel) for B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Target=CD19.
- Yescarta (axicabtagene ciloleucel) for certain types of non-Hodgkin lymphoma, including DLBCL and primary mediastinal large B-cell lymphoma (PMBCL). Target=CD19.
- Tocartus (brexucabtagene autoleucel) for Mantle cell lymphoma (MCL) and Acute lymphoblastic leukemia (ALL). Target=CD19.
- Breyanzi (Isocabtagene maraleucel) – for Diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), High-grade B-cell lymphoma (HGBL), Follicular lymphoma (FL). Target=CD19.
- Abecma (decablagene vicieuce) for Multiple Myeloma. Target= BCMA.
- Carvykti (citacabitogene autoleuce) for Multiple Myeloma. Target= BCMA.
It's always essential for patients and their caregivers to discuss specific treatment options, potential benefits, and risks with their healthcare providers to make informed decisions.
Video credit: The video Journal of Hematology and Hematological Oncology
